- The Company reports that its Indian collaborator and drug sponsor, Karveer Meditech Pvt. Ltd., India, has communicated that approximately 26 out of the target of 36 healthy volunteers in the various cohorts in the Phase 1a Single-Ascending-Dose ("SAD") have already completed the study. Additionally, 17 out of the target of 36 healthy volunteers in the various cohorts in the Phase 1b Multiple-Ascending-Dose ("MAD") part of the clinical trial have already completed the study.
- No adverse events or serious adverse events were found in the SAD or MAD studies to date, in either the NV-CoV-2 Oral Syrup or the NV-CoV-2 Oral Gummies administration cohorts.
Nanoviricides Reported That The Phase 1a/1b Human Clinical Trial Of NV-CoV-2, The Company's Broad-spectrum Antiviral Drug, Is Progressing Successfully
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.